A Bearish Assessment on Biotech ETFs

The iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB), the largest biotech exchange traded fund by assets, is off more than 5% over the past month, bringing its year-to-date loss to just over 20%. That is enough to put IBB in bear market territory for the year and with post-election enthusiasm for biotech stocks and ETFs faltering,…Click to read more at ETFtrends.com.